ReviewNature reviews. Rheumatology2011
Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.
Review in Nature reviews. Rheumatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Association Between Systemic Lupus Erythematosus and Cancer Morbidity and Mortality: Findings From Cohort Studies.Frontiers in oncology · 2022Pooled it
- Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies.Frontiers in pharmacology · 2019Pooled it
- Pooled it
- Single-cell mass cytometry cartography highlights systemic lupus erythematosus and Sjögren's disease immune differences.Frontiers in immunology · 2026Article
- Development of Diffuse Large B Cell Lymphoma in a Patient with Systemic Lupus Erythematosus within Two Years after the Initiation of Anifrolumab and Mycophenolate Mofetil Treatment.Internal medicine (Tokyo, Japan) · 2025Article
- Amlexanox inhibits production of type I interferon and suppresses B cell differentiationRMD open · 2025Article
- Disentangling the Complex Relationships Between Autoimmune Diseases and Cancer Through Polygenic Risk Scores: Evidence from a Large Prospective Study.Research square · 2025Article
- Autoimmune disease-associated lymphomas: research progress and review.Frontiers in immunology · 2025Review
- Concomitant manifestations of systemic lupus erythematosus flare-up and nodal marginal zone B-cell lymphoma in a 41-year-old male patient: A challenging case report.Clinical case reports · 2024Article
- Comparison of Comorbidity Models Within a Population-Based Cohort of Older Adults With Non-Hodgkin Lymphoma.JCO clinical cancer informatics · 2024Article
- The interconnected roles of TRIM21/Ro52 in systemic lupus erythematosus, primary Sjögren's syndrome, cancers, and cancer metabolism.Cancer cell international · 2023Review
- Primary colonic MALT lymphoma associated with Crohn's disease: Case report and review of the literature.Clinical case reports · 2023Article
- The causal effect of inflammatory bowel disease on diffuse large B-cell lymphoma: two-sample Mendelian randomization study.Frontiers in immunology · 2023Article
- Primary cutaneous diffuse large B-cell lymphoma after total knee arthroplasty: a case study and a systematic review of its cutaneous manifestations and treatment options.Postepy dermatologii i alergologii · 2022Article
- The five major autoimmune diseases increase the risk of cancer: epidemiological data from a large-scale cohort study in China.Cancer communications (London, England) · 2022Article
- Article
- Case Report: Rapid Progression of Cognitive Dysfunction as an Initial Feature of Systemic Lupus Erythematosus With Leukoencephalopathy: A Case Report and Literature Review.Frontiers in neurology · 2022Article
- Lymphomagenesis predictors and related pathogenesis.Journal of translational autoimmunity · 2021Review
- Review
- Diffuse large B cell lymphoma in a preceding IgG4-related disease with kidney restricted lambda light chain expression: case report and literature review.BMC nephrology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune rheumatic diseases (ARD), such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's syndrome (SS), have consistently been associated with the development of B-cell non-Hodgkin lymphoma (BCNHL). In this Review, we focus on reports published since 2006 and summarize the data regarding the BCNHL subtypes and clinical findings associated with this increased risk. Patients with these ARD, particularly those with detectable autoantibodies and systemic involvement, are at increased risk of developing BCNHL, especially diffuse large B-cell lymphoma and marginal zone lymphoma. SS shows the strongest association with BCNHL. Male sex, advanced age, prolonged disease course and increased disease severity, but not family history of autoimmune conditions, seem to be associated with an increased risk of non-Hodgkin lymphoma. Chronic immune stimulation, genetic and environmental factors and some immunosuppressive drugs might be involved in lymphomagenesis in these patients. The reason why some ARD are associated with BCNHL and other autoimmune diseases are not remains unclear. These associations are important as they provide information about the mechanisms of lymphomagenesis, and might help identify new therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.